

This material is an English translation of the press release announced on August 17, 2015 in Japanese, and the Japanese release is given priority about the content and the interpretation.

August 17, 2015

**Notification of the Marketing Approval of MOHRUS® PAP XR  
a topical analgesic and anti-inflammatory product**

Hisamitsu Pharmaceutical Co., Inc. (Head Office: Tosu city, Saga prefecture, Japan; Chairman and CEO: Hirotaka Nakatomi, hereinafter referred to as Hisamitsu) hereby announces that Hisamitsu has been approved for manufacturing and marketing for “MOHRUS® PAP XR 60mg” and “MOHRUS® PAP XR 120mg”, a topical analgesic and anti-inflammatory product (Generic name: ketoprofen, hereinafter referred to as “the product” )

The product is new addition of “MOHRUS®TAPE(once a day)” , a topical analgesic and anti-inflammatory product which is the main product of Hisamitsu. The product has the same indications as “MOHRUS®TAPE”

This is a topical analgesic and anti-inflammatory product developed as a gel patch-form drug (once a day) using Hisamitsu’s TDDS (transdermal drug delivery system) technology.

We are confident that this new addition will further contribute to analgesic drug treatment.

※Reference

Trade name	MOHRUS® PAP XR 60mg MOHRUS® PAP XR 120mg
Generic name	Ketoprofen
Indication	<ul style="list-style-type: none"><li>● Pain and inflammation relief from the following disorders and symptoms Lower back pain (muscle/myofascial, osteoarthritis of the spine, intervertebral disc disease,lumbar strain), osteoarthritis, shoulder peri-arthritis, tendon/tendonitis, inflammation around the tendon, humeral epicondylitis (tennis elbow, etc.), muscle pain and swelling and aches caused by external injuries.</li><li>● Localized joint pain relief in rheumatoid arthritis</li></ul>
Dosage and administration	Applying to the affected area once a day
Size of patch	7cm×10cm (MOHRUS® PAP XR 60mg) 10cm×14cm (MOHRUS® PAP XR 120mg)